Cargando…

Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study

BACKGROUND: The COVID-19 pandemic has had significant impacts on how mental health services are delivered to patients throughout Canada. The reduction of in-person healthcare services have created unique challenges for individuals with psychotic disorders that require regular clinic visits to admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKee, Kyle A., Crocker, Candice E., Tibbo, Philip G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687150/ https://www.ncbi.nlm.nih.gov/pubmed/34930204 http://dx.doi.org/10.1186/s12888-021-03646-9

Ejemplares similares

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Comparison of hospitalizations in patients on first generation versus second generation long acting injectable (LAI) antipsychotics
por: Rasool, Seemab, et al.
Publicado: (2021)

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing
por: Piacentino, D., et al.
Publicado: (2022)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
por: Lin, Yao-Yu, et al.
Publicado: (2023)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
por: Prajapati, Asta R, et al.
Publicado: (2016)

Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa
por: Veyej, Nabila, et al.
Publicado: (2022)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Lais /
por: France, Marie de
Publicado: (1994)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia
por: Crocker, Candice E., et al.
Publicado: (2018)

Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia
por: Crocker, Candice E., et al.
Publicado: (2018)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

UbaLAI is a monomeric Type IIE restriction enzyme
por: Sasnauskas, Giedrius, et al.
Publicado: (2017)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

PM499. Improvement of cognitive function before and after 2-year treatment with long-acting injection (LAI) of antipsychotics evaluated by NIRS using single word-induced hemoglobin variation as an index
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
por: Paton, Carol, et al.
Publicado: (2021)

Mental health adverse events with cannabis use diagnosed in the Emergency Department: what are we finding now and are our findings accurate?
por: Crocker, Candice E., et al.
Publicado: (2023)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions
por: Gannon, Jessica M., et al.
Publicado: (2020)

Examination of the impact of COVID-19 public health quarantine measures on acute mental health care services: A retrospective observational study
por: Nejati, Nadine, et al.
Publicado: (2021)

Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics
por: Carr, Chelsea N., et al.
Publicado: (2016)

Does prescribing long acting antipsychotic injection increase mortality or morbidity in patients who continue to use illicit drugs?
por: Sud, N.
Publicado: (2023)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ien0gjmvcitja3ri1meputd5i9